Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts Review released its analysts' notes regarding Community Health Systems, Inc. (NYSE: CYH), United Therapeutics Corporation (NASDAQ: UTHR), Thoratec Corp. (NASDAQ: THOR), Albany Molecular Research Inc. (NASDAQ: AMRI), and Cytokinetics, Inc. (NASDAQ: CYTK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
Community Health Systems, Inc. Analyst Notes
On February 27, 2014, Community Health Systems, Inc.'s (Community Health Systems) stock rose 2.57% to end the day at $42.25 compared to the previous day's closing price of $41.19. The Company's stock went down 1.42% over the past three trading days, compared to the Dow Jones Industrial Average which rose 0.40% during the same trading period. The full analyst notes on Community Health Systems, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/CYH/report.pdf
United Therapeutics Corporation Analyst Notes
On February 25, 2014, United Therapeutics Corp. (United Therapeutics) reported its Q4 2013 and full-year 2013 financial results. For the quarter, the Company reported total revenues of $289.0 million compared to $243.8 million in Q4 2012, while annual revenues came in at $1.1 billion compared to $916.1 million for full year 2012. Net loss totaled $30.3 million or $0.60 per diluted share for Q4 2013 compared to net income of $83.3 million or $1.60 per diluted share in Q4 2012. For its full-year 2013, net income totaled $174.6 million or $3.28 per diluted share, compared to $305.4 million, or $5.71 per diluted share in full year 2012. Commenting on the results, Martine Rothblatt, Ph.D., United Therapeutics' Chairman and CEO, stated, "United Therapeutics continued to deliver strong results in 2013, reflecting growing demand for our Remodulin®, Tyvaso® and Adcirca® products. In addition we successfully brought a fourth product, Orenitram™, to FDA approval and continued enrolling patients in two pivotal trials with the goal of demonstrating that our oral prostacyclin analogues reduce morbidity and mortality in patients with pulmonary arterial hypertension." The full analyst notes on United Therapeutics Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03052014/UTHR/report.pdf
Thoratec Corp. Analyst Notes
On February 26, 2014, Thoratec Corp. (Thoratec) announced that the Company will be participating in the Barclays Global Healthcare Conference, which is scheduled on March 11, 2014, Tuesday. The Company stated that the presentation will be led by Taylor C. Harris, Vice President and CFO, and will begin at 9:00 a.m. EDT or 6:00 a.m. PDT. Thoratec added that a webcast of the presentation will be available at the Company's website. The full analyst notes on Thoratec Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/THOR/report.pdf
Albany Molecular Research Inc. Analyst Notes
On February 27, 2014, Albany Molecular Research Inc. (AMRI) announced that it will be presenting at the Barclays Global Healthcare Conference on March 12, 2014, Wednesday at 2:00 p.m. ET. According to the Company, William S. Marth, President and CEO of AMRI, will represent the Company at the conference. AMRI stated that a webcast of the presentation can be accessed at the Investor Relations' section of the Company's website, where it will be archived for 90 days after the presentation. The full analyst notes on Albany Molecular Research Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/AMRI/report.pdf
Cytokinetics, Inc. Analyst Notes
On February 25, 2014, Cytokinetics, Inc. (Cytokinetics) announced the closing of an underwritten public offering of 4,375,000 shares of its common stock, along with 656,250 additional shares of its common stock in accordance with the full exercise of the underwriters' option to purchase additional shares. The Company stated that the public offering price was $8.00 per share and total net proceeds to Cytokinetics from the public offering are expected to be c.$37.4 million, after deducting the underwriting discount and estimated offering expenses payable by Cytokinetics. Cytokinetics added that it plans to use these net proceeds for research and development and other general corporate purposes, including working capital. The full analyst notes on Cytokinetics, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/CYTK/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article